Condensed Consolidated Statement of Cash Flows (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash Flow From (Used in) Operating Activities:
Net earnings	$ 375	$ 544
Adjustments to reconcile earnings to net cash from operating activities -
Depreciation	224	222
Amortization of intangibles	174	199
Share-based compensation	119	126
Trade receivables	82	(10)
Inventories	(90)	(132)
Other, net	(548)	(489)
Net Cash From Operating Activities	336	460
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment	(255)	(274)
Purchases of investment securities, net	(367)	(1,834)
Other	27
Net Cash (Used in) Investing Activities	(595)	(2,108)
Cash Flow From (Used in) Financing Activities:
Proceeds from issuance of short-term debt and other	1,213	2,248
Transfer of cash and cash equivalents to AbbVie Inc.		(5,901)
Purchases of common shares	(2,192)	(925)
Proceeds from stock options exercised, including income tax benefit	170	69
Dividends paid	(343)	(224)
Net Cash (Used in) Financing Activities	(1,152)	(4,733)
Effect of exchange rate changes on cash and cash equivalents	(4)	(48)
Net Decrease in Cash and Cash Equivalents	(1,415)	(6,429)
Cash and Cash Equivalents, Beginning of Year	3,475	10,802
Cash and Cash Equivalents, End of Period	$ 2,060	$ 4,373